Congratulations to Precision Health Economics, and in particular the Evidence Strategy, Generation, and Communication (ESGC) practice group, for their outstanding efforts in support of the development of new legislation and FDA guidelines allowing biopharmaceutical manufacturers to more proactively share clinical and economic information with population health decision-makers on emerging therapies.
Precision for Value Senior Vice President Jorge Font, MPH will be presenting at the 2017 Asembia Specialty Pharmacy Summit with Mercer’s national pharmacy practice leader, David Dross, on the topic of Employer Perspectives on Specialty Pharmacy: Continued Focus on Controlling Rising Costs. The presentation will take place on April 30th at 2:00pm.
Precision for Value’s Larry Blandford offers a new commentary in STAT First Opinion, insisting that payers and the pharmaceutical industry come together to develop a value-based drug reimbursement system. He suggests taking a page from the playbook developed for electronic prescribing as the key to moving forward.
FiercePharma interviews precisioneffect’s Carolyn Morgan and Deborah Lotterman, showcasing the creative concepts behind Precision’s buzz-worthy Boston subway takeover ad campaign.
Jeremy Schafer and Maureen Hennessey promote antimicrobial stewardship in a new commentary for Managed Healthcare Executive, offering 4 specific steps: rewarding antimicrobial stewardship, leveraging quality scores, implementing appropriate controls, and the establishment of patient education campaigns.
Precision for Value’s Kelly Wilder is interviewed by PharmaVoice and provides her perspectives on the payer landscape, the definition of value, and best practices for pharmaceutical companies.
The recent AMCP presentation by Precision for Value’s Jeremy Schafer and Maureen Hennessey, “The Present and Future of Oncology Care Management” is highlighted in the latest edition of Managed Healthcare Executive.
Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.
Congratulations to PHE authors Joanna MacEwan, Jason Shafrin, and Darius Lakdawalla who, along with coauthors Felicia Forma, Ainslie Hatch, and Jean-Pierre Lindenmayer, have been awarded the 2017 JMCP Award for Excellence.
The JMCP Award for Excellence is an annual award recognizing a single article that represents the best scholarly work in managed care pharmacy. The paper, “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed With Schizophrenia,” brings a cutting-edge statistical technique to the analysis of adherence to serious mental illness medicines.